ARS Pharmaceuticals, Inc (SPRY) Stock Analysis

ARS Pharmaceuticals, Inc (SPRY) is a publicly traded company in the HEALTHCARE sector. It trades at $7.94, carries a market capitalization of $782.51M. This page summarizes the public market data, fundamentals, and frequently asked questions for SPRY, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Price: $7.94
Market Cap: $782.51M
EPS: $-1.95
52-Week High: $18.63
52-Week Low: $6.66

Market Sentiment

ARS Pharmaceuticals, Inc currently has a Neutral sentiment score of -0.08.

About ARS Pharmaceuticals, Inc

ARS Pharmaceuticals, Inc. is an innovative biopharmaceutical company based in San Diego, California, focused on developing ARS-1, an advanced intranasal epinephrine aerosol designed to provide rapid relief for individuals at risk of life-threatening allergic reactions. By leveraging proprietary absorption technology, ARS-1 aims to improve the accessibility and usability of epinephrine delivery, catering to the needs of patients and their families. The company's commitment to addressing critic...

GNG Research Analysis

GNG Research scores ARS Pharmaceuticals, Inc (SPRY) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SPRY.

Frequently Asked Questions

Does SPRY pay dividends?

ARS Pharmaceuticals, Inc (SPRY) does not currently pay a regular dividend.

What is SPRY's market cap?

ARS Pharmaceuticals, Inc (SPRY) has a market capitalization of $782.51M with a current stock price of $7.94.